Skip to main content
Article thumbnail
Location of Repository

Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gαq/11 Coupling in a Schizophrenia Endophenotype

By Hasib Salah-Uddin, Elizabeth Scarr, Geoffrey Pavey, Kriss Harris, Jim J. Hagan, Brian Dean, R. A. John Challiss and Jeannette M. Watson


Alterations in muscarinic acetylcholine receptor (CHRM) populations have been implicated in the pathology of schizophrenia. Here we have assessed whether the receptor function of the M1 subtype (CHRM1) is altered in a sub-population of patients with schizophrenia, defined by marked (60–80%) reductions in cortical [3H]-pirenzepine (PZP) binding, and termed ‘muscarinic receptor-deficit schizophrenia’ (MRDS). Using a [35S]-GTPγS-Gαq/11 immunocapture method we have assessed whether CHRM1 signalling in human cortex (Brodmann area 9 (BA9)) is altered in post mortem tissue from a MRDS group compared with a subgroup of patients with schizophrenia displaying normal PZP binding, and controls with no known history of psychiatric or neurological disorders. The CHRM agonist (oxotremorine-M) and a CHRM1-selective agonist (AC-42) increased Gαq/11-[35S]-GTPγS binding, with AC-42 producing responses that were ~50% of those maximally evoked by the full agonist, oxotremorine-M, in control and subgroups of patients with schizophrenia. However, the potency of oxotremorine-M to stimulate Gαq/11-[35S]-GTPγS binding was significantly decreased in the MRDS group (pEC50 (M)=5.69±0.16) compared with the control group (6.17±0.10) and the non-MRDS group (6.05±0.07). The levels of Gαq/11 protein present in BA9 did not vary with diagnosis. Maximal oxotremorine-M-stimulated Gαq/11-[35S]-GTPγS binding in BA9 membranes was significantly increased in the MRDS group compared with the control group. Similar, though non-statistically significant, trends were observed for AC-42. These data provide evidence that both orthosterically and allosterically acting CHRM agonists can stimulate a receptor-driven functional response ([35S]-GTPγS binding to Gαq/11) in membranes prepared from post mortem human dorsolateral prefrontal cortex of patients with schizophrenia and controls . Furthermore, in a subgroup of patients with schizophrenia displaying markedly decreased PZP binding (MRDS) we have shown that although agonist potency may decrease, the efficacy of CHRM1-Gαq/11 coupling increases, suggesting an adaptative change in receptor-G protein coupling efficiency in this endophenotype of patients with schizophrenia

Publisher: Nature Publishing Group
Year: 2009
DOI identifier: 10.1038/npp.2009.41
OAI identifier:

Suggested articles


  1. (2002). Acute cholinergic rescue of synaptic plasticity in the neurodegenerating cortex of anti-nerve-growth-factor mice. doi
  2. (2007). Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry doi
  3. (1999). Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophrenia Res doi
  4. (2007). Comparison of the in vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine. doi
  5. (2008). Decreased cortical muscarinic receptors define a sub-group of subjects with schizophrenia. Mol Psychiatry 2008; [advance online publication, doi
  6. (1990). Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia. doi
  7. (2007). Muscarinic acetylcholine receptor knockout mice: novel phenotypes and clinical implications. Nat Rev Drug Discov doi
  8. (2007). Neuroimaging of cognitive disability in schizophrenia: Search for a pathophysiological mechanism. Int Rev Psychiatry doi
  9. (2006). No change in cortical muscarinic M2, M3 receptors, or [35S]-GTPγS binding in schizophrenia. Life Sci doi
  10. (2008). Pharmacological assessment of M1 muscarinic acetylcholine receptor-Gq/11 protein coupling in membranes prepared from post mortem human brain tissue J Pharmacol Exp Ther doi
  11. (2003). Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. doi
  12. (2001). Relation of prefrontal cortex dysfunction to working memory and symptoms in schizophrenia. doi
  13. (2007). Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.